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Abstract
The number of individuals diagnosed with metabolic syndrome has risen dramatically in recent years. Although 
not a disease itself, metabolic syndrome significantly raises the risk of developing cardiovascular disease and type 
2 diabetes mellitus, both considered to be epidemics. Therefore, it is critical to promote aggressive therapies that 
effectively combat conditions associated with the metabolic syndrome. However, treating metabolic syndrome is 
complicated due to the complex nature of its pathophysiology coinciding with the many health abnormalities metabolic 
syndrome is often associated with, including but not limited to, insulin resistance, central obesity, hypertension, and 
atherogenic dyslipidemia. One promising compound that has been demonstrated to alleviate metabolic syndrome is 
fiber. The various types of fiber work through multiple mechanisms of action in the human body and can potentially 
result in weight loss in addition to blood glucose control and the lowering of cholesterol. Therefore, increasing intake 
of dietary fiber might prevent or even reverse some of the negative health anomalies associated with metabolic 
syndrome. The purpose of this review is to provide a cursory overview of the core components of metabolic syndrome 
and address how fiber intake may combat these conditions.
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Introduction
It has been established that patients diagnosed with metabolic 
syndrome (MS) have significantly greater incidence of developing type 
2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) [1-3]. 
Indeed, diabetes is a nationwide epidemic in the United States affecting 
nearly 26 million Americans, with 90-95% of these cases being T2DM 
[4]. The monetary costs for diabetes alone accounts for an estimated 
245 billion dollars in the United States annually [5]. CVD is the primary 
cause of death in people with T2DM [6,7] and ranks number one in 
fatalities worldwide [8]. Similar to increased incidences of individuals 
with T2DM, diagnosis of people with MS is steadily rising [9].
It has been proposed that fiber may assist in the regulation of 
abnormalities that are commonly linked with MS [10-13]. Dietary 
fiber is capable of a diverse array of positive health effects due to 
different mechanisms of action in various types of fibers. Ingestion of 
fiber may have a pronounced effect on combating MS, both directly 
and indirectly, via influencing physiological pathways that deal with 
nutrient uptake, energy balance, appetite, satiety, and waste excretion. 
The purpose of this review is to provide an understanding of the health 
conditions and risks linked to MS and how dietary fiber may prevent 
or even reverse some of the health abnormalities associated with MS.
Metabolic Syndrome
While MS is considered to be a relatively new concept, there have 
traditionally been four main conditions associated with MS; insulin 
resistance (IR), obesity, hypertension, and dyslipidemia [14]. However, 
the International Diabetes Federation offered a novel proposition 
characterizing MS [15,16]. The International Diabetes Federation 
deemed central obesity (CO) and atherogenic dyslipidemia as core 
components for the diagnosis of MS and used them to replace obesity and 
dyslipidemia, respectively [15]. Furthermore, the waist circumference 
values to diagnose CO for the International Diabetes Federation are race 
and ethnic specific, which innovatively established unique diagnostic 
criteria. The International Diabetes Federation also emphasized the 
important relationship of proinflammatory and prothrombotic states 
to MS [15]. Though difficult to discern, prothrombosis and systemic 
inflammation are serious consequences of MS. It has been noted that 
both CVD and T2DM are considered to be inflammatory diseases [17, 
18] and it is recognized that most cardiovascular events are caused 
by a thrombus [19]. The latest consensus among MS experts is that 
proinflammatory and prothromtotic states are prevalent in individuals 
having metabolic risk factors for MS [20]. It is also important to 
mention that no single risk factor appears to be most important in 
terms of mortality [21]. Thus, understanding the pathophysiology of 
all components plus best ways to treat these conditions and MS as a 
whole is crucial.
Central Obesity
The International Diabetes Federation declares CO to be the 
only mandatory criteria for diagnosis of MS [16]. CO is excessive 
accumulation of visceral adipose tissue. This is often correlated with IR 
[21-23]. CO may be more detrimental to proper glucose metabolism 
as overweight or even obese people with proportional body fat do 
not always show signs of IR [24], while in some cases normal weight 
individuals with excessive visceral adiposity may display IR [25].
Compared with subcutaneous adipose tissue, visceral adipose 
tissue is a more active tissue in two distinct ways. First, visceral adipose 
tissue is more metabolically active than subcutaneous adipose tissue 
due to increased adrenergic activity as visceral fat has more beta 
adrenergic receptors and is more sensitive to lipolytic catecholamine 
effects compared with subcutaneous fat [26-30]. Excess visceral adipose 
tissue triggers an abundant release of free fatty acids (FFA) that spill 
into the hepatic portal vein, quickly making their way to the liver and 
exacerbating IR [31]. Marked increases in FFA elevate triglycerides in 
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the body [32,33], which are one of the main features of atherogenic 
dyslipidemia [15]. Increases in FFA also reduce insulin clearance 
[31,34] which is a strong indicator of IR [34]. Second, visceral adipose 
tissue is more hormonally active compared to subcutaneous adipose 
tissue. Visceral adipose tissue initiates key inflammatory proteins, 
namely interleukin-6, tumor necrosis factor alpha, and C-reactive 
protein, all of which have been linked or associated with IR [35-38].
Insulin Resistance
IR can be simply stated as, “a state where there is a reduced biologic 
effect for any given concentration of insulin” [39]. IR is believed 
to be a key player in triggering MS pathogenesis [40]. IR appears to 
originate from a weakened response to insulin in glucose-responsive 
cells [41]. More specifically, hyperinsulinemia occurs postprandially 
when glucose cannot be sufficiently cleared from the bloodstream by 
myocytes, resulting in de novo lipogenesis and atherogenic dyslipidemia 
[42]. Hyperinsulinemia causes a subsequent downregulation of insulin 
receptors, impairing insulin function [43,44]. Consequently, constant 
long-term hyperinsulinemia intensifies IR and plays a direct role in the 
development of T2DM [45,46].
Atherogenic Dyslipidemia
Atherogenic dyslipidemia is a critical factor in developing CVD 
related to MS. While atherogenic dyslipidemia plays a prominent role 
in the development of atherosclerosis, endothelial dysfunction works 
alongside atherogenic dyslipidemia to contribute to the development 
of CVD [47], as endothelial dysfunction also promotes atherosclerotic 
plaque development [48,49]. This effect may provide to be synergistic 
in patients with MS, as endothelial dysfunction is predominantly 
found in this population [50]. Other modes of action exist in MS which 
directly influence atherogenic dyslipidemia. Elevated FFA, commonly 
observed as a result from IR, accumulate in the liver causing a high 
FFA flux. This can result in increased production of very low density 
lipoproteins, triglycerides, apolipoprotein B, and a reduction in high 
density lipoproteins [31]. High triglycerides and apolipoprotein B 
along with low levels of high density lipoproteins are known to be 
atherogenic [51] and their respective concentrations are used to 
determine atherogenic dyslipidemia [15].
The negative effects of atherogenic dyslipidemia can be manipulated 
by hormonal factors. As mentioned earlier, the adipokines interleukin-6 
and tumor necrosis factor alpha can be generated from visceral adipose 
tissue [35-38]. Tumor necrosis factor alpha and interleukin-6 inhibit the 
secretion of adiponectin, an adipokine that displays anti-atherogenic 
effects [52,53]. Anti-atherogenic capabilities of adiponectin include 
inhibition of monocytes attaching to endothelial walls, resulting in 
down regulation of scavenger receptors which prevents foam cells from 
changing into macrophages [54]. This lack of protection may increase 
the susceptibility of atherosclerotic plaque to develop from atherogenic 
dyslipidemia present in individuals suffering from MS.
Hypertension
Hypertension associated with MS may originate from several 
participating factors. These factors may include the degree of 
sympathetic activity within the central nervous system, adjustments in 
salt sensitivity and management in the kidneys, endothelin-1 mediated 
vasoconstriction, and angiotensin II [55]. Moreover, increases in FFA 
have been shown to impair vascular reactivity in humans [56] which 
is detrimental to sustaining normal blood pressure. CO has also been 
considered to influence hypertension, being an even stronger risk 
factor than general obesity [57]. Visceral adipose tissue secretes more 
angiotensinogen than subcutaneous fat [58,59] which may increase 
blood pressure via altering the renin-angiotensin system through 
increasing this system’s main substrate (angiotensinogen) resulting in 
vasoconstriction.
Normal insulin signaling is critical in maintaining normal blood 
pressure and alterations in insulin signaling may result in hypertension 
[57]. Insulin is known to increase the release of nitric oxide which 
causes vasodilatation [60]. The end result of this is a potential drop 
in blood pressure. However, as seen with IR, disturbances to the 
endothelium may evolve which might prevent an insulin induced-nitric 
oxide vasodilatation effect [61], possibly resulting in hypertension. The 
consequences of both IR and hypertension is thought to be particularly 
detrimental to health and markedly increases the chance of developing 
CVD compared to just suffering from one of these ailments [62].
Systemic Inflammation
There appears to be a strong relationship between MS and 
inflammation [63]. The type of inflammation commonly seen in patients 
suffering from MS is a chronic, low-grade inflammation coined systemic 
inflammation. Indeed, adipocytes are able to produce adipokines that 
may lead to a proinflammatory state [64]. Many different adipokines 
are quite capable of producing systemic inflammation. However, the 
adipokines interleukin-6, C-reactive protein, and tumor necrosis 
factor alpha in particular show extensive systemic inflammation 
exacerbation, as these adipokines are also cytokines with acute phase 
and/or immune responses as their underlying purpose/operation in 
the body. Interleukin-6 can initiate systemic inflammation on its own 
as well as intensify systemic inflammation by augmenting secretion 
of interleukin-1 and tumor necrosis factor alpha [65]. High levels of 
C-reactive protein have been linked to T2DM and CVD in addition 
to being a strong marker for systemic inflammation [66]. Though it 
has been suggested that IR amplifies the state of proinflammation with 
systemic inflammation as the end outcome [31, 55], there are also 
hypotheses supporting the notion that IR can result from systemic 
inflammation [67,68].
Prothrombosis
A recent concern of MS is the relationship with prothrombosis 
and increased CVD risk. In a prothrombotic state, a dangerous clot 
can form if a vulnerable plaque ruptures [69]. Fibrinolysis impairment 
may cause vascular damage and initiate obstructions of the circulatory 
system inherently increasing CVD risk [70-75]. Prothrombosis in 
people with MS may be due to the negative synergy associated to 
smaller amounts of tissue plasminogen activator secreted in correlation 
with higher concentrations of the adipokine plasminogen activator 
inhibitor-1 being secreted from the outcome of insulin resistance 
and glucose intolerance [70-73,75]. The enzyme tissue plasminogen 
activator catalyzes the conversion of plasminogen to plasmin, 
an enzyme essential to fibrinolysis, while plasminogen activator 
inhibitor-1 is the primary inhibitor of tissue plasminogen activator. 
If plasminogen activator inhibitor-1 and tissue plasminogen activator 
levels attributed to prothrombosis remain unchanged, repeated bouts 
of unwanted coagulation may ensue, which when combined with 
atherosclerosis [70-76], increases the chance of a cardiovascular event. 
While prothrombosis is a major risk factor for CVD, as a thrombus 
is virtually considered a requisite for the most fatal type of CVD (i.e. 
myocardial infarction), prothrombotic states shouldn’t raise incidence 
for T2DM. Other conditions of MS though, such as CO, IR, and 
systemic inflammation, increase the risk of both CVD and T2DM.
Nevertheless, all conditions of MS should be taken seriously and 
attempted to be alleviated as they are thought to work in synergistic 
fashion to markedly increase incidence of T2DM and/or CVD.
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the brain while the low RS diet showed a fasted state instead, suggesting 
RS as a factor in controlling hunger [97].
Increasing fiber intake may also have a profound impact on 
positively influencing body composition changes, too. Positive 
changes in body composition may aid in the prevention or treatment 
of metabolic syndrome as increased skeletal muscle mass may have 
protective qualities against MS [98]. Rodents fed a low or high RS 
chow had substantial differences in body composition, favoring the 
anti-obesity effects of high RS intake [97,99]. While mean body weights 
were comparable among both groups, lean body mass was higher in 
the high RS group. The high RS group also exhibited lowers visceral, 
subcutaneous, and intra hepatocellular fat content when compared to 
the low RS group [97,99]. The lower visceral fat level observed in these 
studies is of utmost importance regarding MS since excessive visceral 
fat causes CO. Thus, possibly changing body composition through 
decreasing visceral adipose tissue by consuming RS may treat CO. By 
reducing CO through the ingestion of RS, other conditions of MS may 
be alleviated as well, such as IR and systemic inflammation, which may 
effectively combat MS.
Glycemic Control
Dietary fiber has been shown to effectively regulate both IR and 
T2DM [100]. Fiber has the unique ability to adsorb certain molecules 
within the gastrointestinal tract. Enzymes involved with carbohydrate 
digestion may be affected by viscous fibers creating a wall that hinders 
their action as a catalyst [101]. Fiber viscosity is particularly important 
by temporarily suspending glucose assimilation, slowing transfer time, 
lowering blood glucose concentrations, and having a positive influence 
upon hormone responses, such as insulin and glucagon-like peptide 1, 
ultimately influencing nutrient uptake [102-105]. In addition to these 
unique features, data from epidemiological studies discovered a inverse 
correlation with insoluble fiber intake and developing T2DM [106,107]. 
RS can lengthen time duration of glucose entering the bloodstream, 
which has a potent, direct effect on regulating blood glucose. RS slows 
the rate at which glucose reaches the blood which has been observed 
in vitro [108] and in vivo in humans [109]. Prolonging glucose into 
the bloodstream may act synergistically by positively influencing 
body composition and satiety by causing less insulin to be secreted 
and increasing the likelihood of lipolysis in addition to controlling 
hunger and maintaining normal body weight [110,111]. This has been 
previously substantiated from clinical research performed comparing 
two similar foods originating from potato starch [112, 113]. In these 
studies, one type of potato starch was raw and contained RS but the 
other type of potato starch was pre-gelatinized and did not contain any 
RS. The RS group from the first study resulted in significantly lower 
blood insulin levels plus better postprandial satiety than their non-RS 
counterparts [112]. Lipolysis was also demonstrated to be higher in the 
RS group compared to the non-RS group [113], which may indicate a 
shift in fatty acids utilized as an efficient energy source instead of used 
for triglyceride synthesis and storage.
RS may also assist in blood glucose regulation through preventing 
IR via manipulating fat location and adipocyte size in the body. In 
two rodent studies previously mentioned [97,99], a ratio of insulin 
to glucose was higher in the low RS group compared to their high RS 
counterparts, suggesting an IR state. It was also noted that the low RS set 
had significantly higher levels of intrahepatocellular fat [97,99]. It may 
be plausible to assume that the higher intrahepatocellular fat content 
may have initiated IR displayed in these studies. Surmounting evidence 
has observed positive correlations between intrahepatocellular fat and 
IR, with speculation that hepatic steatosis may play a chief role in the 
Fiber
Dietary fiber comes from a variety of food sources, in particular 
fruits, vegetables, legumes, nuts, and whole grains. A common method 
of grouping fiber types is determining their solubility in water. Soluble 
fibers dissolve in water while insoluble fibers do not [77]. An approximate 
ratio for many fibrous foods is 2/3 of insoluble fiber to every 1/3 of soluble 
fiber [78]. The third type of fiber, named Resistant Starch (RS), comprises 
of either starch and/or products resulting from starch digestion in humans 
bypassing digestion that would normally occur in the small intestine 
consequently entering the large bowel [79]. It should be noted RS only 
comes from starch that is not fully digested [80].
Reputable health organizations have recognized fiber as an 
invaluable nutrient. Both the World Health Organization and 
World Cancer Research Fund have emphasized that dietary fiber 
can help prevent obesity and weight gain [81,82]. Additionally, a 
joint consultation on human nutrition by the Food and Agriculture 
Organization of the United Nations and World Health Organization 
previously explained that a significant advance in realizing key vital 
health attributes of carbohydrates in the past twenty years has been 
due to discovering RS [83]. Furthermore, the National Academy of 
Sciences Food and Nutrition Board acknowledged RS as a beneficial 
carbohydrate [84]. 
Substantial evidence indicates fiber may contain numerous factors 
which promote many distinct health benefits [85]. Moreover, it 
appears that fiber consumption and markers of metabolic syndrome 
are inversely correlated with one another [86]. Additionally, it has 
been acknowledged that over 90% of the adult population fails to meet 
adequate intake recommendations for fiber [87]. Therefore, increasing 
fiber intake may prove to be beneficial for the vast majority of adults 
suffering from MS.
Appetite Control, Satiety and Positive Body Composition 
Change
Dietary fiber may provide satiety [88,89] resulting in a decreased 
caloric intake and improved weight loss. Achieving weight loss through 
a hypocaloric has shown to effectively combat metabolic syndrome by 
reducing central obesity, blood pressure, fasting glucose and insulin, 
triglycerides, C-reactive protein, low density lipoproteins, and 
increasing high density lipoproteins and insulin sensitivity [90]. Soluble 
fibers capable of holding large volumes of water and able to create 
viscous gels within the gastrointestinal tract have shown to temporary 
suspend gastric emptying into the duodenum, slowing down digestion 
and providing a longer duration of satiety after meals [91,92].
Insoluble fibers can control appetite by acting as a powerful 
bulking agent. Insoluble fibers are extremely resilient to fermentation 
by bacteria inside the colon [93] which may increase fecal matter 
both directly and indirectly. Insoluble fibers which are excreted 
through the colon may take-up other fermentable carbohydrates with 
them as well, allowing them to pass the fermentation process and be 
excreted as waste instead [93]. This bulking effect in turn significantly 
increases gastrointestinal load which may promote satiety and create 
a feeling of fullness. Research has also shown insoluble fiber assists in 
reducing overall caloric consumption shortly after meals [94] as well as 
promoting weight loss [95,96].
RS starch may also promote satiety and curb hunger. A study 
analyzed rodent brains to evaluate possible changes when being fed 
either a high RS diet or a low RS diet [97]. Rodents fed the high RS diet 
displayed a state similar to a satiated animal in hypothalamic regions of 
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pathogenesis of IR [114,115]. Additionally, since larger adipocyte size 
is known to reduce insulin sensitivity [116], this may partially attribute 
to the insulin resistant states observed, as the low RS diet resulted in 
a considerably larger adipocyte size in comparison to rats fed a high 
RS diet [97]. Thus, it may be possible for a type of synergistic ability to 
occur through the consumption of various fibers resulting in decreasing 
adipocyte size, hepatic steatosis, and blood glucose concentrations, 
ultimately improving IR and preventing the progression of T2DM.
Atherogenic Dyslipidemia Treatment & Cardiovascular 
Disease Prevention
Positive lipid alterations known to lessen the chance of CVD have 
been observed with fiber consumption [117]. Soluble fibers as well as 
the insoluble fibers such as lignin and specific types of chitosan are 
capable of adsorbing bile acids, fatty acids, and cholesterol, with these 
fiber attached molecules likely passing the small intestine and the end 
result being broken down by bacteria inside the large intestine or simply 
excreted with feces, resulting in less overall cholesterol and bile acids 
inside the body to be absorbed by the liver. Lowered levels of cholesterol 
within the liver may initiate low density lipoproteins (LDL) to be cleared 
from the blood. Inadequate amounts of bile acids absorbed by the liver 
triggers the production of new bile acids from the utilization of cholesterol. 
Both of these effects decrease serum cholesterol [118]. Short chain fatty 
acids (SCFA), byproducts of fiber fermentation in the colon has also been 
shown to lower cholesterol [119,120]. The mechanism of action, that SCFA 
decrease cholesterol is via reducing cholesterol synthesis rate [119]. Fiber 
also has the ability to influence the atherogenic dyslipidemia markers 
triglycerides and apolipoprotein B concentrations in the body as well. 
Evidence has indicated soluble fiber capable of lowering both triglyceride 
and apolipoprotein B levels [121]. Though the improvement of all 
conditions of MS is critical to health and well-being, treating atherogenic 
dyslipidemia and lessening the chance of CVD is of utmost importance in 
reducing mortality in patients suffering from MS, as not only is CVD 
more prevalent in individuals with MS but more people with MS die 
from CVD as well [122,123]. 
Final Remarks
Fiber has been previously recognized as a potential candidate to 
assist in treating MS [10-13]. An intake of a variety of fibers may be the 
most appropriate way of combating MS versus just increasing one class 
of dietary fiber. Diets high in fiber may also have therapeutic capabilities 
for alleviating certain MS amnolies similar to drug treatment. In 
particular, a fiber rich diet known as the dietary portfolio or portfolio 
diet, but colliquolly called the “Jenkins diet” has been shown to lower 
cholesterol as effectively as statin therapy in healthy adults suffering 
from hyperlipidemia [124]. Since increasing fiber intake may preclude 
medication, is non-invasive, and is only counterproductive at very 
high levels [125,126], it may be wise to consume a high fiber diet. Fiber 
from foods may be a better approach to obtaining daily fiber rather 
than from supplementation. Aside from the higher nutrient profile 
fiber rich foods display when compared to fiber supplements, it has 
been projected that increasing fiber consumption via consuming whole 
grains, fruits, vegetables, and legumes would significantly reduce 
obesity in industrialized nations [127].
Consumption of dietary fibers causes an array of different 
biochemical reactions in line with the kind of fiber being ingested. 
Therefore, this acknowledgment should be incorporated into treatment 
of MS as well. It is also imperative to recognize fibers that promote 
health benefits by decreasing T2DM and CVD risk, as these are the 
two diseases that are significantly increased in people who have MS [1-
3]. For example, whole grain intake is correlated with lowered risk of 
T2DM, heart disease, and stroke [128]. Evidence supports the notion 
that the lower whole grain consumption is in populations, the rate of 
incidence rises for individuals developing MS [129,130]. Whole grains 
are known to contain ample amounts of dietary fibers [131]. Whole 
grains may effectively alleviate MS by promoting satiety and weight 
loss primarily from the mid-section, improve blood glucose, lipid, and 
insulin levels, and lower blood pressure and inflammation [132-138].
In general, soluble fiber may be able to positively alter blood lipids 
[139]. Specific types of soluble fiber though may have an even more 
prominent effect on other conditions of metabolic syndrome, such as IR, 
hypertension, systemic inflammation, and oxidative stress [121,140] in 
addition to the benefits upon plasma cholesterol and triglyceride levels 
[121]. Cereal fiber is another type of fiber that appears very promising 
with the intent of preventing MS [130]. Cereal fiber intake coincides 
with decreasing the chance of developing T2DM [141-145] as well as 
lowering CVD risks [107]. Also, raising cereal fiber consumption in the 
diet enhances insulin sensitivity [146]. 
Future studies are needed to discover exactly which fibrous 
components display positive effects upon the treatment of MS, as well 
as the ones which may cause negative conditions. It has already been 
suggested that fiber may increase prothrombosis [147-150], but more 
recent literature contests this [151]. Unfortunately, data in pertinence 
to this topic is brief and anachronous in relation to MS. Future studies 
should try to determine whether fiber increases blood coagulation or 
not. Furthermore, investigations should be performed to understand 
both the direct and indirect mechanisms of action these fiber 
components have relating to the pathophysiology of MS. It certainly 
should not be ignored that a higher fiber diet may result in notable 
weight loss, which may also alleviate conditions of MS. Therefore, 
until clinical trials are conducted that actually demonstrate a causal 
inference regarding fiber preventing and/or treating MS independent 
of other factors (e.g. weight loss), caution should be exercised. If 
however certain components of fiber do indeed have a profound 
impact on alleviating certain conditions of MS, then extraction of these 
substances for medicinal and/or supplementation purposes may in 
fact be applied for use in the future of individuals suffering from MS. 
Nevertheless, if this were employed into modern practice one day, a 
high intake of whole grains, fruits, vegetables, nuts, seeds, and legumes 
would still be commended for the many numerous health benefits they 
provide other than their respected fiber contents.
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